berkeley-biotech
(4)
Aralez Bio
Aralez Bio is a Berkeley, California biotechnology company that uses engineered enzymes and directed evolution to manufacture noncanonical amino acids (ncAAs) - the specialized building blocks used in peptide drugs and other pharmaceuticals. Spun out of Nobel Laureate Frances Arnold's Caltech lab in 2019, the company runs biocatalytic reactions that produce enantiopure ncAAs in a single step with water as the main byproduct, expanding the amino acid toolbox roughly 1,000-fold. Aralez sells a catalog of thousands of exclusive amino acids and offers custom synthesis and ton-scale production for pharmaceutical customers, including partners among the world's largest drug companies.
HexemBio
HexemBio is a New York- and Berkeley-based biotech building what it calls the first blood stem cell rejuvenation therapy. Its Synthetic Human Yolk Sac platform recreates the embryonic environment where blood stem cells first arise, temporarily placing a patient's own aged hematopoietic stem cells into that synthetic young niche before returning them by IV infusion - rather than gene-editing or chemically reprogramming the cells. The company launched publicly in April 2026 with a $10.4M seed round led by Draper Associates, holds an FDA Orphan Drug Designation for a bone-marrow-transplant program in blood cancers, and is targeting first-in-human trials in 2027.
Timothy Craven
Timothy Craven is the co-founder and CEO of Insamo, a Berkeley-based biotech using machine learning, ultra high-throughput biology, and parallel chemistry to design membrane-permeable, orally available macrocyclic peptides with antibody-like binding. A computational chemist trained in the Nobel-winning lab of David Baker, Craven started Insamo from a grad-school concept with $20,000 of his own money and grew it into a Berkeley-Sydney team backed by a $12M seed from Playground Global, venBio, and Merck's MRL Ventures Fund. His pitch is blunt: turn $30,000 injectable biologics into pills.
Newomics, Inc.
Newomics is a Berkeley, California biotechnology company building mass spectrometry front-end hardware for precision medicine. Spun out of Lawrence Berkeley National Laboratory, its silicon multinozzle emitter (M3) and MnESI ion source upgrade existing mass spectrometers to deliver microflow robustness with nanospray sensitivity, enabling higher-throughput, higher-sensitivity multiomics across proteomics, metabolomics, lipidomics, native MS and single-cell analysis. The company sells to pharmaceutical, academic and government labs and co-markets with major instrument vendors like Thermo Fisher Scientific.